

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

DATE OF BOARD MEETING

The board (the “**Board**”) of directors (the “**Directors**”) of Alphamab Oncology (the “**Company**”) announces that a meeting of the Board will be held on August 15, 2024, Thursday for the purpose of, inter alia, considering and approving the interim results of the Company and its subsidiaries for the six months ended June 30, 2024 and its publication and transacting any other business.

By order of the Board

Alphamab Oncology

Dr. XU Ting

Chairman and Executive Director

Hong Kong, August 2, 2024

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as independent non-executive Directors.